KALISPELL, Mont. and MOUNT PLEASANT, Texas, June 24, 2025 (GLOBE NEWSWIRE) -- Glacier Bancorp, Inc. ("Glacier" or the "Company") (NYSE: GBCI) and Guaranty Bancshares, Inc. ("Guaranty") (NYSE: GNTY), the bank holding company for Guaranty Bank & Trust, N.A., a leading community bank headquartered in Mount Pleasant, Texas, today jointly announced the signing of a definitive agreement, pursuant to which Glacier will acquire Guaranty in an all-stock transaction. The acquisition marks Glacier's 27th bank acquisit ...

LONG BEACH, Calif. and TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX: GHBWF), one of the fastest-growing, vertically integrated cannabis companies in the U.S., announces that, at the Company's annual and special meeting (the "Meeting") of shareholders that was held on June 20, 2025 at 11:00 a.m. (Pacific Time), the Company's shareholders passed all of the resolutions put before them. At the M ...

Toronto, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Spirit Blockchain Capital Inc. (CSE: SPIR), a leading public company advancing regulated digital asset and tokenization strategies, is pleased to announce the appointment of Don Stewart, CFA, to its Board of Directors as an Independent Board Member. Mr. Stewart brings a distinguished blend of leadership in capital markets, public service, and financial regulation that will significantly enhance Spirit’s governance and strategic execution. A veteran of Bay S ...

Core Insights - Cue Biopharma, Inc. has received positive Pre-IND feedback from the FDA regarding its lead autoimmune asset, CUE-401, a first-in-class bispecific molecule designed to induce and expand regulatory T cells (Tregs) in vivo [1][2] - CUE-401 utilizes the combined activities of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2) to potentially provide durable immune rebalance and tolerance for various autoimmune diseases [2][4] Company Overview - Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics that selectively engage and modulate disease-specific T cells for autoimmune disease treatment [1][8] - The company’s proprietary platform, Immuno-STAT™, aims to harness the body's intrinsic immune system without the adverse effects of broad systemic immune modulation [8] Product Details - CUE-401 is engineered to enhance the Treg induction capacity of TGF-β combined with IL-2 signaling, which is believed to improve the quality and stability of Tregs [5][6] - The design of CUE-401 allows for "conditional binding," which minimizes off-target activity and simplifies manufacturing processes [6] Mechanism of Action - CUE-401 acts as a master switch to convert autoreactive effector T cells into stable, induced T-regulatory cells (iTregs), establishing a 'tolerance positive feedback loop' that increases nonspecific Treg populations while reducing autoreactive T cells [7]

Core Insights - Coherent Corp. will showcase its innovative photonics products and technologies at Laser World of Photonics 2025 in Munich, Germany, from June 24-27 [1][2] - The event serves as a global platform for demonstrating advancements in photonics, highlighting Coherent's role in shaping the industry's future through transformative technologies and partnerships [2] Recent Product Announcements - The introduction of an industry-first 600W excimer laser that doubles throughput and triples runtime for high-volume HTS tape production, supporting applications in fusion energy and MRI [3] - Launch of an 18W 880 nm single-emitter laser diode designed for efficient pumping of DPSS lasers, enhancing performance in industrial and scientific applications [4] - A new two-micron thulium fiber laser aimed at improving precision and efficiency in urology treatments, offering compact and energy-efficient solutions [5] - High-performance disposable surgical fibers designed for laser lithotripsy and medical procedures, providing superior durability and energy transmission [6] - A compact 500W air-cooled diode laser system for polymer welding, simplifying OEM integration and enhancing productivity [7] - The FACTOR series diode pumps now feature higher output power and new wavelengths, supporting scalable production for medical and industrial applications [8] - The expanded PowerMax™ line includes a new high-power sensor capable of measuring laser power up to 15 kW, enhancing safety and accuracy in industrial environments [8] Integrated Photonics Forum - The opening keynote titled "Unlocking Revolutionary Frontiers in Technology" will be presented by Dr. Sanjai Parthasarathi on June 24 [9] - Various talks and panel discussions will cover trends, challenges, and advancements in the industrial laser industry, featuring multiple expert speakers throughout the event [15]

Core Viewpoint - Coherent Corp. has launched the ACE FL series, a thulium fiber laser designed for therapeutic medical applications, particularly for lithotripsy and benign prostatic hyperplasia (BPH) treatment [1][2]. Group 1: Product Features and Benefits - The ACE FL system offers superior precision, improved patient outcomes, and enhanced procedural efficiency compared to traditional laser technologies like holmium:YAG systems [2]. - Thulium fiber lasers provide superior cutting precision in BPH enucleation, a compact form factor for OEM integration, and enhanced energy efficiency through lower power consumption and improved thermal management [3]. Group 2: Market Position and Opportunities - The shift towards outpatient and minimally invasive procedures creates a strong market opportunity for fiber-based surgical lasers [3]. - Coherent's ACE FL platform utilizes proprietary fiber designs and manufacturing capabilities, offering OEM partners a scalable, high-performance solution for next-generation surgical tools [4]. Group 3: Manufacturing and Innovation - Coherent's vertically integrated manufacturing and IP-protected fiber designs position the company to support global medical device manufacturers with reliable supply and long-term innovation [5]. - The ACE FL series will be showcased at LASER World of Photonics Munich 2025, highlighting the company's commitment to innovation in the photonics industry [5].

Core Viewpoint - Farmers & Merchants Bancorp, Inc. has announced a quarterly cash dividend of $0.22125 per share, reflecting its commitment to returning capital to shareholders [1][2]. Group 1: Dividend Announcement - The Board of Directors approved a quarterly cash dividend of $0.22125 per share, payable on July 20, 2025, to shareholders of record as of July 7, 2025 [1]. - F&M has a history of paying quarterly dividends for over 50 years and has increased its annual dividend for 30 consecutive years [2]. Group 2: Company Overview - Farmers & Merchants Bancorp, Inc. is the holding company for F&M Bank, which has total assets of $3.39 billion as of March 31, 2025 [1]. - F&M Bank has been serving its communities since 1897, providing commercial and retail banking services across various counties in Ohio and parts of Indiana and Michigan [3].

LOUDON, Tenn., June 24, 2025 (GLOBE NEWSWIRE) -- Malibu Boats, Inc. (Nasdaq: MBUU), a leading designer, manufacturer and marketer of a diverse range of recreational powerboats, announced today that Melanie Cook, former Chief Operating Officer of GE Appliances, has been appointed to the Company’s Board of Directors as an independent director, effective immediately. Ms. Cook will serve on the Audit Committee and the Nominating and Governance Committee. “We are excited to welcome Melanie to our board,” said Mi ...

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today announced voting results of its 2025 annual general and special meeting of shareholders held today, June 24, 2025, in Toronto. A total of 5,222,899 common shares in the capital of the Company (“Common Shares”), or 29% of Electra’s issued and outstanding Common Shares were represented in person or by proxy at the meeting. Shareholders voted in favour of all items of ...

Core Viewpoint - Anterix announced its fiscal 2025 fourth quarter and full year financial results, highlighting significant operational developments and financial metrics [1]. Full Year FY2025 Financial and Operational Highlights - Spectrum revenue for the year ended March 31, 2025, was $6.031 million, an increase from $4.191 million in the previous year, representing a growth of 43.9% [14]. - The company reported a net loss of $11.372 million for the fiscal year, compared to a loss of $9.128 million in the prior year [14]. - Total assets as of March 31, 2025, were $333.104 million, up from $324.894 million a year earlier [12]. Fourth Quarter FY2025 Financial Highlights - In the fourth quarter, spectrum revenue was $1.389 million, compared to $1.260 million in the same quarter of the previous year, marking a 10.2% increase [14]. - The net income for the fourth quarter was $9.208 million, a significant recovery from a net loss of $9.411 million in the same quarter of the previous year [14]. - Operating expenses for the fourth quarter were $12.237 million, down from $13.755 million year-over-year [15]. Liquidity and Balance Sheet - As of March 31, 2025, Anterix had no debt and cash and cash equivalents of $47.4 million, down from $60.578 million a year earlier [4][11]. - The company had a restricted cash balance of $7.7 million in escrow deposits [4]. - The total stockholders' equity was $156.601 million, a decrease from $161.032 million in the previous year [12]. Share Repurchase Program - Anterix has an authorized share repurchase program for up to $250 million, with $227.7 million remaining as of March 31, 2025 [5][21]. - In the fourth quarter, the company repurchased shares totaling $1.955 million, and for the full fiscal year, the total was $8.398 million [5][21]. Strategic Developments - The company executed new spectrum sale agreements totaling $116 million with Oncor Electric Delivery Company and Lower Colorado River Authority [7]. - Anterix launched the AnterixAccelerator™ initiative to promote utility adoption of private broadband networks, which is currently oversubscribed [7]. - The company has a pipeline of approximately $3 billion in prospective contract opportunities across over 60 potential customers [7].